linjc16/ctgov huggingface dataset:
Immunoglobulins Anti Platelets In Breast Milk Of Maternal ITP

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether mothers with Idiopathic thrombocytopenic purpura (ITP) has antibodies against platelets in breastfeeding milk aside control group of healthy mothers. In order to prevent severe thrombocytopenia in infants born to mothers with ITP.

Detailed Description
-----------------
Samples of breastfeeding milk and sera will be collected from 10 lactating women diagnosed with ITP and from 10 healthy women in the same stage after giving birth. Antibodies against platelets in the samples will be examined by using anti human IgM/G/A antibody following incubation of the serum/milk samples with platelets. The platelets will be from leftovers of samples send to platelets functionality test and found to be normal (the platelets samples will be taken without any identification and be marked only with lab number). The measurement will be done by flow cytometer. Sample will be consider as positive when the signal will be greater than 2 fold of control samples standard deviation. In addition, the presence of antibodies in different times from the birth will be checked in breastfeeding milk and sera of ITP patients. If the milk proteins and lipids will disturb the exam, the immunoglobulins from the milk will be isolated using Ig isolation kit from plasma.

Official Title
-----------------
IMMUNOGLOBULINS ANTI PLATELETS IN BREAST MILK OF MATERNAL ITP

Conditions
-----------------
Mothers With ITP Condition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Maternal ITP Newborns above 35W and above 2.5 kg Exclusion Criteria: mothers who do not breast feeding Thrombocytopenia from other reasons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IMMUNOGLOBULINS ANTI PLAITLETS IN BREST MILK OF MATERNAL ITP |  | 4 times in the first month after delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ITP
Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer

Study Overview
=================
Brief Summary
-----------------
This will be a retrospective review of 30 patients with unknown primary cancer who have had commercially available RT-PCR assays performed on biopsied tumors, in order to determine if the assay results are consistent with clinical features and useful for planning initial therapy or changing therapy.

Official Title
-----------------
Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer: Role in Clinical Management and Primary Site Prediction

Conditions
-----------------
Unknown Primary Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with RT-PCR testing completed since commercialization of the RT-PCR assay in 2007.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To correlate the tissue of origin predicted by the RT-PCR assay with clinical and pathologic features of patients with carcinoma of unknown primary site. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To correlate the tissue of origin predicted by the RT-PCR with actual primary sites found subsequently in a subset of patients. |  | 6 months | 
| To evaluate the utility of RT-PCR assay results in guiding treatment selection in patients with carcinoma of unknown primary site. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RT-PCR molecular profiling assay, Molecular Profiling-Real Time Polymerase Chain Reaction, Unknown Primary, UPC, CUP
Early Active Finger Exercises in Replanted Fingers

Study Overview
=================
Brief Summary
-----------------
A controlled randomized trial, including patients undergoing finger replantation surgery. The Control Group will receive a standardized post operative rehabilitation regime, whilst the Intervention Group will receive a rehabilitation regime that includes early active exercises of the replanted digits.

Official Title
-----------------
Will Early Active Finger Exercises in Replanted Fingers Improve Mobility? A Prospective Randomized Trial

Conditions
-----------------
Amputation

Intervention / Treatment
-----------------
* Other: Active exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years Total or subtotal amputation injury of 1-4 of the four ulnar digits Injury distal to the MCP joint Must have injured flexor tendon which requires suture Must have a fracture Surgery done with a stable osteosynthesis with acceptable post-operative x-ray imaging The finger must have had a stable circulation for at least 5 days post-surgery Exclusion Criteria: Arthrodesis/temporary fixation of the MCP joint Bilateral amputation injury Severely damage of other parts if the hand compromising the patient's ability to perform active exercises of the fingers Patients who cannot follow the planned controls

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone. | |
| Other: Intervention<br>Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist | Other: Active exercises<br>* Active flexion movements every waking hour of the replanted digits<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TAM | Total active movement of the interphalangeal joints | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quick-DASH | Upper extremity function score (patient related outcome measure) | 12 months | 
| VAS Pain | Visual Analogue Score Pain | 12 months | 
| VAS Function | Visual Analogue Score Function | 12 months | 
| Grip strength | Jamar dynanometer | 12 months | 
| Key pinch | Jamar dynamometer | 12 months |
Diagnostic Utility of Exercise Cardiac Magnetic Resonance in the Assessment of Cardiac Dyspnea.

Study Overview
=================
Brief Summary
-----------------
Researchers are examining the diagnostic utility of an exercise cardiac MRI (eCMR) in the assessment of cardiac dyspnea (shortness of breath).

Official Title
-----------------
Diagnostic Utility of Exercise Cardiac Magnetic Resonance in the Assessment of Cardiac Dyspnea.

Conditions
-----------------
Shortness of Breath, Cardiac; Dyspnea

Intervention / Treatment
-----------------
* Diagnostic Test: Exercise cardiac magnetic resonance imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients aged ≥18 years years with suspected cardiac dyspnea who are scheduled to undergo right heart catheterization as dictated by a comprehensive examination and echocardiography will be included for enrollment. Exclusion Criteria: Age <18 years Pregnancy Mechanical ventilation Acute or chronic renal failure (creatinine clearance <30 ml/min or requiring renal replacement therapy) Inability to perform MRI (i.e. claustrophobia, severe obesity (>150 kg), device incompatible with MRI) Inability to exercise Significant arrhythmia that precludes adequate ECG-gating for the MRI (i.e. atrial fibrillation with highly variable cycle lengths) Prior heart or lung transplantation Left ventricular systolic (ejection fraction <50%) or diastolic failure (based on Framingham criteria for heart failure with preserved ejection fraction) Significant left-sided valvular disease (≥moderate aortic stenosis, mitral stenosis, aortic regurgitation, mitral regurgitation) or prior valve surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subjects with unexplained but suspected cardiac dyspnea<br>Subjects with unexplained but suspected cardiac dyspnea who are being scheduled for right heart catheterization will undergo an exercise cardiac magnetic resonance imaging (eCMR). | Diagnostic Test: Exercise cardiac magnetic resonance imaging<br>* Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging<br>* Other names: eCMR;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ejection Fraction | Measured using exercise cardiac magnetic resonance imaging (eCMR) reported in percentages | Baseline | 
| Stroke Volume | Measured using exercise cardiac magnetic resonance imaging (eCMG) reported in mL | Baseline | 
| Longitudinal Strain Assessment | Measured using exercise cardiac magnetic resonance imaging (eCMG) reported in percentages | Baseline |
Prognostic Value of the AMR Measured After PPCI in STEMI Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about in STEMI with Primary PCI Patients. The main questions it aims to answer are: To determine the value of AMR in predicting the long-term clinical prognosis of patients with STEMI after PPCI, and to find the best cut-off value. Analyze the factors of PPCI affecting AMR and explore the effective measures of PPCI microcirculation protection. Radiographic images of STEMI receiving primary PCI treatment in several chest pain centers in China will be included. The last image of the infarct-related vessel will be used as a target to calculate its AMR. The relationship between AMR and long-term clinical prognosis was analyzed.

Official Title
-----------------
Prognostic Value of the Angio-based Microvascular Resistance Use One Single Angiographic View Measured After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients

Conditions
-----------------
Coronary Heart Disease, ST Elevation Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 or older Type 1 myocardial infarction Receive PPCI Exclusion Criteria: Failed to identify culprit vessels. Structural heart disease with moderate to severe aortic valve or mitral regurgitation and or stenosis that may affect cardiac function Dialysis patients with severe renal insufficiency Severe and uncontrollable arrhythmia Complicated with dilated cardiomyopathy Unable to tolerate dual antiplatelet therapy Severe and uncontrollable anemia Hyperthyroidism TIMI blood flow 0-1 grade after PPCI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACEs | cardiac death, hospitalization for heart failure, target vessel revascularization，non-fatal MI | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac death | Rates of individual components of MACE | 12 months | 
| hospitalization for heart failure | Rates of individual components of MACE | 12 months | 
| target vessel revascularization | Rates of individual components of MACE | 12 months | 
| non-fatal MI | Rates of individual components of MACE | 12 months |
Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
Subjects with Obstructive Sleep Apnea (OSA) are at increased risk of developing cardiometabolic complications, and effective long-term nCPAP treatment significantly reduces the risk of cardiovascular morbidity and mortality.

Detailed Description
-----------------
Primary outcome: Incidence of cardiometabolic diseases in subjects with OSA over 9 years. Secondary outcomes: Effects of CPAP treatment on cardiometabolic conditions

Official Title
-----------------
Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea - Prospective 9 Years Follow-up Study

Conditions
-----------------
Obstructive Sleep Apnea, Cardiovascular Diseases, Metabolic Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: From previous cohort for reassessment. Exclusion Criteria: Unstable medical conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cardiometabolic complications | 167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point. | 9 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effects of CPAP treatment on cardiometabolic conditions |  | 9 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive sleep apnea, cardiometabolic complications, Effects of CPAP treatment
Anti-thymocyte Globulin-induced Immune Senescence

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the impact of Anti-Thymocyte Globulin (ATG) on immune senescence. Markers of immune senescence expression is assessed in a prospective cohort of renal transplant recipients the day of transplantation and one year after renal transplantation.

Detailed Description
-----------------
The anti-thymocyte globulin (ATG) are used in the prevention and treatment of acute rejection in organ transplantation. They are at the origin of a brutal CD4 lymphocyte depletion followed by a gradual recovery of the lymphocyte pool. Nevertheless, CD4 lymphopenia can persist in some patients. SIGAL study aims to characterize the immune responses of lymphopenic patients (after administration of ATG) in order to identify possible similarities with immunosenescence.The immunosenescence is a complex and profound remodeling of the immune system during life. It is mainly due to thymic involution and repeated antigenic stimulation.

Official Title
-----------------
Anti-thymocyte Globulin-induced Immune Senescence

Conditions
-----------------
Disorder Related to Renal Transplantation

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient able to understand the reason of the study Signature of informed consent Patient who are waiting renal transplant Exclusion Criteria: Inability to understand the reasons for the study; psychiatric disorders Any history in the last 2 years of immunosuppressive therapy (except steroids) History of cancer (except skin cancer) or treated hematological malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ATG group<br>Patients who received T cell depleting ATG therapy (blood sample one year after transplantation) | Other: Blood sample<br>* A blood sample is performed one year after kidney transplantation.<br>|
| anti-CD25 group<br>Patients who received nondepleting anti-CD25 (blood sample one year after transplantation) | Other: Blood sample<br>* A blood sample is performed one year after kidney transplantation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of senescent lymphocytes | Flow cytometry analysis (7 colors) of lymphocytes | One year after kidney transplantation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kidney transplantation, Immunosuppressive treatment
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to evaluate the efficacy and safety of a fixed-dose escitalopram combination relative to its component monotherapies and to placebo in patients with major depressive disorder.

Official Title
-----------------
Fixed Dose Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Escitalopram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder. The patient's current depressive episode must be at least 12 weeks in duration. Exclusion Criteria: Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control. Patients who currently meet DSM-IV criteria for: a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder. Patients who are considered a suicide risk. Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Escitalopram|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Montgomery Asberg Depression Rating Scale (MADRS) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hamilton Depression Rating Scale (HAMD) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, Major Depressive Disorder, Escitalopram
Endovascular treatmenT for Acute Ischemic Stroke in China

Study Overview
=================
Brief Summary
-----------------
This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.

Official Title
-----------------
Endovascular treatmenT for Acute Ischemic Stroke in China: a Retrospective, National, Multi-center, Registry Study

Conditions
-----------------
Stroke, Endovascular Treatment

Intervention / Treatment
-----------------
* Other: endovascular treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: ≥ 18; Ischemic stroke confirmed by head CT or MRI; Patients receiving endovascular treatment; First ever stroke or mRS≤2 after previous disease; Complete and clear pre- and post-operative DSA images are available Exclusion Criteria: Imaging data not qualified for evaluation; Absence of important clinical data; The first 50 patients receiving endovascular treatment in a single centerr.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: endovascular treatment|all enrolled patients must receive endovascular treatment.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with modified Rankin Score (mRS) 0 to 2 | the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome | Day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in National Institute of Health stroke scale (NIHSS) | the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome | Day 2, 7, 14 | 
| Proportion of patients with modified Rankin Score 0 to 2 | Proportion of patients with modified Rankin Score 0 to 2 | Day180, 360 | 
| Distribution of modified Rankin Score | Distribution of modified Rankin Score after treatment | Day 90, 180, 360 | 
| Proportion of symptomatic intracranial hemorrhage (sICH) | sICH was defined as 4 or more increase in NIHSS caused by hemorrhage | 48 hours | 
| Proportion of intraparenchymal hemorrhage (PH1 and PH2) | Proportion of intraparenchymal hemorrhage (PH1 and PH2) after treatment | 48 hours | 
| Proportion of death | death due to any cause | Day 7 | 
| Changes in cerebral edema | edema is determined by middle shift. | 48 hours, 7 days |